Free Trial

Avacta Group (AVCT) Competitors

Avacta Group logo
GBX 57.10 -0.92 (-1.59%)
As of 12:37 PM Eastern

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

Should you buy Avacta Group stock or one of its competitors? Avacta Group's main competitors and comparable companies include Oxford Biomedica (OXB), Silence Therapeutics (SLN), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), and Arix Bioscience (ARIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avacta Group compare to Oxford Biomedica?

Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Oxford Biomedica has a net margin of -23.23% compared to Avacta Group's net margin of -35,730.97%. Oxford Biomedica's return on equity of -54.51% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-35,730.97% -1,293.07% -21.80%
Oxford Biomedica -23.23%-54.51%-12.67%

In the previous week, Oxford Biomedica had 1 more articles in the media than Avacta Group. MarketBeat recorded 2 mentions for Oxford Biomedica and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.00 beat Oxford Biomedica's score of -0.81 indicating that Avacta Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avacta Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oxford Biomedica
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative

Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.106, suggesting that its share price is 11% more volatile than the broader market.

2.9% of Avacta Group shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 49.1% of Avacta Group shares are owned by insiders. Comparatively, 43.3% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£113K2,218.30-£30.08M-£9.24N/A
Oxford Biomedica£175.36M3.66-£143.51M-£31.96N/A

Oxford Biomedica has a consensus price target of GBX 818, indicating a potential upside of 54.63%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts clearly believe Oxford Biomedica is more favorable than Avacta Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Oxford Biomedica beats Avacta Group on 9 of the 16 factors compared between the two stocks.

How does Avacta Group compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company Overall Sentiment
Silence Therapeutics Neutral
Avacta Group Neutral

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -35,730.97%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
Avacta Group -35,730.97%-1,293.07%-21.80%

2.9% of Avacta Group shares are held by institutional investors. 49.1% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Silence Therapeutics has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
Avacta Group£113K2,218.30-£30.08M-£9.24N/A

Summary

Avacta Group beats Silence Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Avacta Group (LON:AVCT) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£113K2,218.30-£30.08M-£9.24N/A
Horizon Discovery Group plc (HZD.L)£54.63M0.00N/A-£5.50N/A

2.9% of Avacta Group shares are held by institutional investors. 49.1% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Avacta Group had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Horizon Discovery Group plc (HZD.L). Avacta Group's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company Overall Sentiment
Avacta Group Neutral
Horizon Discovery Group plc (HZD.L) Neutral

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Avacta Group's net margin of -35,730.97%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-35,730.97% -1,293.07% -21.80%
Horizon Discovery Group plc (HZD.L) N/A N/A N/A

Summary

Horizon Discovery Group plc (HZD.L) beats Avacta Group on 5 of the 9 factors compared between the two stocks.

How does Avacta Group compare to PureTech Health?

Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

2.9% of Avacta Group shares are owned by institutional investors. Comparatively, 31.4% of PureTech Health shares are owned by institutional investors. 49.1% of Avacta Group shares are owned by company insiders. Comparatively, 13.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avacta Group has higher earnings, but lower revenue than PureTech Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£113K2,218.30-£30.08M-£9.24N/A
PureTech Health£6.37M46.46-£91.86MN/AN/A

PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 321.23%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Avacta Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Avacta Group and Avacta Group both had 1 articles in the media. PureTech Health's average media sentiment score of 0.75 beat Avacta Group's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avacta Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PureTech Health
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PureTech Health has a net margin of 7.53% compared to Avacta Group's net margin of -35,730.97%. PureTech Health's return on equity of 0.14% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-35,730.97% -1,293.07% -21.80%
PureTech Health 7.53%0.14%-13.39%

Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, indicating that its share price is 23% less volatile than the broader market.

Summary

PureTech Health beats Avacta Group on 10 of the 14 factors compared between the two stocks.

How does Avacta Group compare to Arix Bioscience?

Avacta Group (LON:AVCT) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

In the previous week, Avacta Group had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Arix Bioscience. Avacta Group's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Avacta Group Neutral
Arix Bioscience Neutral

Arix Bioscience has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£113K2,218.30-£30.08M-£9.24N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

Arix Bioscience has a net margin of 105.64% compared to Avacta Group's net margin of -35,730.97%. Arix Bioscience's return on equity of 6.41% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-35,730.97% -1,293.07% -21.80%
Arix Bioscience 105.64%6.41%2.18%

Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

2.9% of Avacta Group shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 49.1% of Avacta Group shares are owned by insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Arix Bioscience beats Avacta Group on 8 of the 11 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVCT vs. The Competition

MetricAvacta GroupBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£249.89M£4.11B£7.88B£2.84B
Dividend Yield3.97%3.64%2.47%5.11%
P/E Ratio-6.1824.5133.3323.37
Price / Sales2,211.4015.118.125.05
Price / Cash15.0021.8921.0220.23
Price / Book3.884.414.802.51
Net Income-£30.08M-£24.19M£3.52B£5.88B
7 Day Performance6.93%-6.16%-4.56%-0.01%
1 Month Performance-14.78%-3.80%-2.78%-2.15%
1 Year Performance-27.26%-3.50%0.12%7.21%

Avacta Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVCT
Avacta Group
N/AGBX 57.10
-1.6%
N/A-26.1%£249.89M£113KN/A120
OXB
Oxford Biomedica
3.2721 of 5 stars
GBX 546
+0.2%
GBX 818
+49.8%
-12.0%£660.92M£175.36MN/A891
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35MN/A100
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63MN/A416
PRTC
PureTech Health
1.9708 of 5 stars
GBX 119.40
-2.3%
GBX 508
+325.5%
-2.6%£292.75M£6.37MN/A300

Related Companies and Tools


This page (LON:AVCT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners